RESEARCH
Immune exclusion signature predicts shorter survival in high-risk stage II colon cancerIn the phase 3 TOSCA trial, a transcriptional signature characterized by low immune cell infiltration and high TGF-β signaling was observed in 28% of high-risk stage II patients and associated with shorter disease-free survival (HR=2.22, p=0.036). (Translational Oncology)